Industry News

 Elan Corp., based in Dublin, Ireland, may consolidate New Jersey and San Francisco units of its pharmaceuticals division at a new North American headquarters in Sorrento Valley, where its recently-acquired Dura Pharmaceuticals is located. Plans would include expanding research space at the existing facility and possibly constructing an additional structure nearby. Elan focuses on drug development for pain management, cancer, and neurological disorders.

 <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />

EOS, a private genomic research company, will relocate from its 31,000-sf space in South San Francisco, to a 82,000-sf building at Slough Estates USA's $250 million development at Oyster Point. Construction of the facility is scheduled to begin in July 2001.

The Southeast Texas BioTechnology Park, a $633 million project announced in February, is seeking funds to continue. The 15-building complex, to be built over 20 years, is backed by a coalition including institutions at the Texas Medical Center, biotechnology companies, professional groups, and governmental entities.

Investigen, an Alameda, Calif.-based biotechnology company, plans to build a 27,000-sf facility on a 1.8-acre site at the North Shore Business Park in Hercules. Investigen expects to occupy 17,000 sf of the structure, subleasing the remaining 17,000 sf.

 MedImmune announced plans in May 2001 to build a huge campus-style 750,000-sf headquarters on 25 acres in Gaithersburg. Construction of phase one of the three-phase project will be a $70 million, 210,000-sf complex scheduled for completion in late 2002. The two-building structure will accommodate 60,000 sf of R&D space and 150,000 sf of administrative space. Amenities will include a covered parking lot, a cafeteria, and health club. Hellmuth, Obata and Kassabaum of St. Louis is designing the facility, which will be built by Quadrangle Development of Washington.